Please wait while the formulary information is being retrieved.
DIPHENOXYLATE-ATROPINE (DIPHENOXYLATE HCL/ATROPINE SULFATE)
- Diarrhea
2.5 mg-0.025 mg tablet
- 2 tablets (5 mg) by oral route 4 times per day as needed
2.5 mg-0.025 mg tablet
- 2 tablets (5 mg) by oral route 4 times per day as needed
2.5 mg-0.025 mg tablet
- 2 tablets (5 mg) by oral route 4 times per day as needed
Diarrhea
- 2 tablets (5 mg) by oral route once daily
- 2 tablets (5 mg) by oral route 2 times per day
- 2 tablets (5 mg) by oral route 3 times per day
- 2 tablets (5 mg) by oral route once daily as needed
- 2 tablets (5 mg) by oral route 4 times per day as needed
- 2 tablets (5 mg) by oral route 4 times per day
- 2 tablets (5 mg) by oral route 3 times per day as needed
- 2 tablets (5 mg) by oral route 2 times per day as needed
- Depade
- naltrexone
- naltrexone microspheres
- pramlintide
- Revia
- Symlinpen 120
- Symlinpen 60
- Vivitrol
Contraindicated
- K-tab
- Klor-con
- Klor-con 10
- Klor-con M10
- Klor-con M15
- Klor-con M20
- Medi-lyte
- potassium chloride
- potassium citrate
- potassium Cl-calcium phos-mag
- sodium Cl-potassium chloride
- Thermotabs
- Urocit-k 10
- Urocit-k 15
- Urocit-k 5
Severe
Moderate
- Adasuve
- Buprenex
- buprenorphine
- buprenorphine-naloxone
- butorphanol tartrate
- Butrans
- chlorpromazine
- Compazine
- Compro
- Fanatrex
- fluphenazine decanoate
- fluphenazine HCl
- gabapentin
- gabapentin enacarbil
- Gralise
- Gralise 30-day Starter Pack
- Haldol
- Haldol Decanoate
- haloperidol
- haloperidol decanoate
- haloperidol lactate
- Horizant
- loxapine
- loxapine succinate
- Loxitane
- nalbuphine
- Neurontin
- perphenazine
- perphenazine-amitriptyline
- Phenadoz
- Phenergan
- prochlorperazine
- prochlorperazine Edisylate
- prochlorperazine maleate
- promethazine
- Promethazine Vc
- Promethazine Vc-codeine
- promethazine-codeine
- promethazine-DM
- promethazine-phenyleph-codeine
- promethazine-phenylephrine
- Promethegan
- Suboxone
- thioridazine
- trifluoperazine
- Zubsolv
- Clostridium difficile infection
- Obstructive hyperbilirubinemia
- Toxin-mediated diarrhea
Contraindicated
- Dehydration
- Diarrhea due to e. coli
- Disease of liver
- Gastroenteritis due to salmonella
- Gastroenteritis due to shigella
- Hepatorenal syndrome
- Severe ulcerative colitis
Severe
Moderate
- Alcoholism
- Angle-closure glaucoma
- Infectious diarrhea
- Kidney disease with reduction in GFR
DIPHENOXYLATE-ATROPINE (DIPHENOXYLATE HCL/ATROPINE SULFATE)
- Diarrhea
- None
- None
More Frequent
Severe
Less Severe
- None
- Acute abdominal pain
- Nausea
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Pancreatitis
- Paralytic ileus
- Toxic megacolon
- Urinary retention
Less Severe
- Acute confusion
- Anorexia
- Blurred vision
- CNS depression
- Depression
- Dizziness
- Drowsy
- Dry skin
- Dysuria
- Euphoria
- Fever
- Flushing
- Gingivostomatitis
- Hallucinations
- Headache disorder
- Hypesthesia
- Malaise
- Nervousness
- Pruritus of skin
- Sedation
- Skin rash
- Tachycardia
- Urticaria
- Vomiting
- Xerostomia
Contraindicated
Diphenoxylate
Risk of respiratory and CNS depression. Contraindicated age < 6 years.
- 1 Day – 6 Years
- 1 Risk of respiratory and CNS depression. Contraindicated age < 6 years.
Severe Precaution
Diphenoxylate
Risk of respiratory and CNS depression, atropinism in Down's syndrome.
- 6 Years – 13 Years
- Risk of respiratory and CNS depression, atropinism in Down's syndrome.
Management or Monitoring Precaution
Atropine
Infants and children are more sensitive to anticholinergic and adverse effects. Adverse CNS effects onset may be sooner and with lower dose.
Monitor for respiratory and CNS depression, atropinism in Down's syndrome.
- 1 Day – 13 Years
- Infants and children are more sensitive to anticholinergic and adverse effects. Adverse CNS effects onset may be sooner and with lower dose.
- 13 Years – 18 Years
- Infants and children are more sensitive to anticholinergic and adverse effects. Adverse CNS effects onset may be sooner and with lower dose.
Diphenoxylate
Infants and children are more sensitive to anticholinergic and adverse effects. Adverse CNS effects onset may be sooner and with lower dose.
Monitor for respiratory and CNS depression, atropinism in Down's syndrome.
- 1 Day – 13 Years
- Monitor for respiratory and CNS depression, atropinism in Down's syndrome.
- 13 Years – 18 Years
- Monitor for respiratory and CNS depression, atropinism in Down's syndrome.
Atropine Sulfate (systemic)
- Severity Level:
2
- Additional Notes: Iv use may produce tachycardia in fetus
Diphenoxylate Hcl
- Severity Level:
C
- Additional Notes: Category c in combination product with atropine
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Atropine
None
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | None |
Diphenoxylate Hcl
None
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Atropine
Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Cardiovascular-May cause orthostatic hypotension at higher doses. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
Risk for sedation, worsening confusion, falls, urinary retention or constipation.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
Diphenoxylate
Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Cardiovascular-May cause orthostatic hypotension at higher doses. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
Risk for sedation, worsening confusion, falls, urinary retention or constipation.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | Y | N | Y | Y | N |
BEERS: N HEDIS: N STOPP: Y
No Known Risk
None
- None
| Diarrhea | |
| K59.1 | Functional diarrhea |
| P78.3 | Noninfective neonatal diarrhea |
| R19.7 | Diarrhea, unspecified |
| 0-9 | A-Z |
|---|---|
| K59.1 | Functional diarrhea |
| P78.3 | Noninfective neonatal diarrhea |
| R19.7 | Diarrhea, unspecified |
Formulary Reference Tool